

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/027,777	02/23/1998	HANSUELI IMMER	P108099-00001	3626	
75	590 09/17/2003			•	
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC 1050 Connecticut Avenue Suite 600			EXAMI	EXAMINER	
			SCHWA'DRON, RONALD B		
WASHINGTO	N, DC 20036-5339		ART UNIT	PAPER NUMBER	
			1644	200	
			DATE MAILED: 09/17/2003	70	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)				
	09/027,777	IMMER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ron Schwadron, Ph.D.	1644				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	rrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on	<u> </u>					
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ Th	is action is non-final.					
3) Since this application is in condition for allowed closed in accordance with the practice under Disposition of Claims						
4)⊠ Claim(s) <u>35 and 36</u> is/are pending in the applic	cation.					
4a) Of the above claim(s) 35 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>36</u> is/are rejected.						
7) Claim(s) is/are objected to.	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine						
10) The drawing(s) filed on is/are: a) accept	•					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120	arrimer.					
13) △ Acknowledgment is made of a claim for foreign	priority under 35 H S C & 410/a	\ (d\ or (5)				
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 33 0.3.0. § 119(a	)-(a) or (r).				
1. Certified copies of the priority documents	s have been received					
2. Certified copies of the priority documents have been received in Application No. <u>08737927</u> .						
Copies of the certified copies of the prior application from the International Bur     See the attached detailed Office action for a list of the certified copies of the prior application.	ity documents have been receive reau (PCT Rule 17.2(a)).	d in this National Stage				
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received.  15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/027,777

Art Unit: 1644

1. Applicant's election with traverse of the species the peptide of claim 36, part (b) in Paper No. 37 is acknowledged. The traversal is on the ground(s) that are stated in said paper. This is not found persuasive because of the following reasons. Regarding applicants comments, the peptides recited in the claims have different amino acid sequences and are therefore structurally and functionally distinct.

The requirement is still deemed proper and is therefore made FINAL.

- 2. Claim 35 is withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 37.
- 3. Claim 36 is under consideration.
- 4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 5. Claim 36 is rejected under 35 U.S.C. 102(b) as being anticipated by Forssmann et al. (EP 0349545) as evidenced by Nutt et al. (US Patent 5,057,603).

Forssmann et al. teach the peptide recited in claim 36(b) except for the Acm molecule attached to the first Cys (see page 9). Forssmann et al. teach that said peptide would be made using chemical synthetic means using protected amino acid groups including Cys (Acm) (see page 10, Example 3). Forssmann et al. teach that the peptide containing the protective groups is treated with HF (see page 10, Example 3). It is an inherent property of said treatment that it would remove all the protective groups except Cys (Acm) (see Nutt et al., column 8, last paragraph). Therefore, said treatment would yield a peptide that differed from the claimed peptide by having two Cys(Acm). Forssmann et al. teach that the peptide containing the two Cys(Acm) is treated to remove Acm (see page 10, last paragraph of Example 3). Since it would be physically impossible for the two Acm molecules to be removed at exactly the same time, it would

Application/Control Number: 09/027,777

Art Unit: 1644

be expected that treatment would yield a mixture of peptides containing one Cys(Acm) at either residue (before all residues were removed to yield Cys residues free of Acm). The transiently occurring peptide with Cys(Acm) at the first residue of the peptide is the claimed invention and would be expected to occur prior to the formation of Cys(Acm) free peptide.

- 6. No claim is allowed.
- 7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

p/1/

Ron Schwadron, Ph.D.

**Primary Examiner** 

Art Unit 1644